Financial Performance - Net sales for Q3 2025 reached $3,072 million, a 7.3% increase from $2,862 million in Q3 2024[20] - The net loss attributable to DuPont common stockholders for Q3 2025 was $123 million, compared to a net income of $455 million in Q3 2024[20] - Comprehensive loss income for Q3 2025 was $185 million, a significant decrease from a comprehensive income of $859 million in Q3 2024[22] - The company reported a net income from continuing operations of $747 million for the nine months ended September 30, 2025, slightly down from $753 million in 2024[26] - For the three months ended September 30, 2025, net income attributable to common stockholders was $(123) million, compared to $455 million in 2024, representing a decrease of 127%[9] - Earnings per share (EPS) from continuing operations for the three months ended September 30, 2025, was $0.70, down from $1.06 in 2024, a decline of 34%[9] Assets and Liabilities - Total assets as of September 30, 2025, were $38,044 million, an increase from $36,636 million at the end of 2024[24] - Long-term debt rose to $7,049 million as of September 30, 2025, compared to $5,323 million at the end of 2024, indicating a 32.5% increase[24] - DuPont's total liabilities increased to $14,703 million as of September 30, 2025, compared to $12,843 million at the end of 2024[24] - The company’s cash and cash equivalents at the end of Q3 2025 were $3,826 million, up from $1,686 million at the end of Q3 2024[26] - The company’s total assets of discontinued operations were valued at $1.813 billion as of September 30, 2025, down from $3.003 billion at December 31, 2024[60] Acquisitions and Divestitures - DuPont completed the acquisition of Donatelle Plastics for a net purchase price of $365 million, which includes a contingent earn-out liability of $40 million[48] - DuPont signed an agreement to acquire Sinochem for $56 million, with the transaction closing on October 10, 2025[46] - DuPont announced the Aramids Divestiture for a gross consideration of $1.8 billion, expecting to receive approximately $1.2 billion in cash proceeds, a $300 million interest-bearing note, and a $325 million equity interest, with the transaction expected to close in Q1 2026[56] - The Aramids Divestiture resulted in a net loss from discontinued operations of $372 million for Q3 2025 and $1,118 million for the nine months ended September 30, 2025[63] Research and Development - Research and development expenses increased to $140 million in Q3 2025, up from $127 million in Q3 2024, reflecting a 10.2% rise[20] Cash Flow and Operating Activities - Cash provided by operating activities from continuing operations for the nine months ended September 30, 2025, was $1,260 million, down from $1,517 million in the same period of 2024[26] - The company recorded $139 million in acquisition, integration, and separation costs for Q3 2025, compared to $43 million in Q3 2024, primarily related to the Electronics Separation[67] Restructuring and Charges - Restructuring charges for the three months ended September 30, 2025, were $20 million, compared to $21 million for the same period in 2024, while for the nine months ended September 30, 2025, charges were $67 million, up from $56 million in 2024[77] - The 2023-2024 Restructuring Program recorded pre-tax restructuring charges of $174 million, including $101 million in severance and related benefits and $73 million in asset-related charges[80] Environmental and Legal Matters - The company has accrued obligations of $265 million for probable environmental remediation and restoration costs[164] - DuPont's contribution to the Water District Settlement Fund was $400 million, part of a total settlement of $1.185 billion for PFAS-related claims[142][143] - As of September 30, 2025, there are approximately 10,000 personal injury cases filed in the AFFF MDL, with many cases including multiple plaintiffs[148] Shareholder Returns - The company declared dividends of $1.23 per common share, totaling $515 million[31] - The company repurchased a total of 27.9 million shares at an average price of $71.67 per share under the $2 billion accelerated share repurchase transaction[173] Tax and Interest - The effective tax rate on continuing operations for Q3 2025 was 5.8%, significantly lower than 17.9% for Q3 2024, primarily due to the release of a valuation allowance[94] - Interest income for the three months ended September 30, 2025, was $27 million, compared to $14 million for the same period in 2024[84]

Core Insights - DuPont de Nemours, Inc. reported a third-quarter 2025 profit from continuing operations of $308 million, or 70 cents per share, down from $453 million, or $1.06 per share, in the same quarter last year. Adjusted earnings were $1.09 per share, exceeding the Zacks Consensus Estimate of $1.04 [1][8] Financial Performance - DuPont's net sales reached $3,072 million, reflecting a 7% year-over-year increase and surpassing the Zacks Consensus Estimate of $2,627 million. Organic sales grew by 6%, driven by a 7% rise in volume, partially offset by a 1% decline in pricing. Foreign currency had a positive impact of 1% [2] - The ElectronicsCo segment recorded net sales of $1,275 million, an 11% increase year-over-year, beating the Zacks Consensus Estimate of $1,216 million. Organic sales grew 10%, supported by an 11% increase in volume, with a 1% decline in pricing. Semiconductor Technologies experienced high-single-digit organic growth due to strong end-market demand, particularly from advanced nodes and AI technology applications [3] - The IndustrialsCo segment reported net sales of $1,797 million, up 5% year-over-year, but missed the Zacks Consensus Estimate of $2,097 million. Organic sales rose 4%, with a 5% increase in volume, offset by a 1% decline in pricing. Healthcare & Water Technologies showed high-single-digit organic growth [4] Financial Position - At the end of the quarter, DuPont had cash and cash equivalents of $1,955 million, a 6.1% increase year-over-year. Long-term debt stood at $7,049 million, up approximately 31.9%. The company generated operating cash flow from continuing operations of $1,260 million for the nine months ended September 30, 2025 [5] Future Outlook - For the fourth quarter of 2025, DuPont expects net sales of approximately $1,685 million, operating EBITDA of around $385 million, and adjusted EPS of about 43 cents. For the full year 2025, net sales are projected to reach roughly $6,840 million, with operating EBITDA estimated at $1,600 million and adjusted EPS expected to be approximately $1.66 [6] Stock Performance - DuPont's shares have declined by 54.2% over the past year, compared to a 40.3% decline in the industry [7]

Financial Data and Key Metrics Changes - Third quarter sales reached $3.1 billion, reflecting a 6% organic growth [5][12] - Operating EBITDA was $840 million, an increase of 6% year-over-year, resulting in an operating EBITDA margin of 27.3% [6][12] - Adjusted EPS for the quarter was $1.09, flat compared to the previous year, primarily due to a higher tax rate [15][20] Business Line Data and Key Metrics Changes - Industrials Co. reported net sales of $1.8 billion, up 5% year-over-year, with organic growth of 4% [15][16] - Electronics Co. saw net sales of $1.3 billion, an increase of 11% year-over-year, with organic growth of 10% [17] - Organic growth in healthcare and water technologies was in the high single digits, driven by strong demand in medical packaging and biopharma [16][80] Market Data and Key Metrics Changes - North America and Asia-Pacific regions experienced organic sales growth of 7%, while Europe saw a 6% increase year-over-year [14] - The construction market remains weak, with expectations of a 4% decline in the shelter business for the year [82] Company Strategy and Development Direction - The company is focused on driving above-market organic growth and building a robust business system [8][11] - A balanced capital allocation model is being deployed, including a $2 billion share repurchase authorization and a quarterly dividend of $0.20 per share [7][20] - The company aims for medium-term targets of 3%-4% organic growth and 150-200 basis points of margin expansion from 2026 to 2028 [11][92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving medium-term targets, with healthcare and water businesses expected to grow at around 5% [32][92] - The company anticipates a gradual recovery in the construction market, with expectations of flat performance in the shelter business next year [82][93] - Management highlighted the importance of operational excellence and lean initiatives to drive productivity and margin improvements [44][70] Other Important Information - The successful completion of the CUNY separation was announced, with $4.2 billion received to reduce debt [18] - The company is actively pursuing M&A opportunities, particularly in healthcare and water sectors, while maintaining a strong balance sheet [39][57] Q&A Session Summary Question: Can you provide insight into the timing benefit related to order shifts? - Management clarified that the timing benefit was customer-driven, as orders were accelerated into Q3 due to a planned blackout period for the separation [28][30] Question: What are the expectations for 2026 and the healthcare and water businesses? - Management expects healthcare and water to align with medium-term targets of about 5% organic growth, while the diversified industrials segment is projected to remain flat [32][92] Question: What is the plan for the balance sheet and potential M&A activity? - The company aims to maintain pro forma debt below 2 times EBITDA and is looking at both share buybacks and M&A opportunities, particularly in healthcare [39][42] Question: Can you elaborate on the strategic rationale for the RO acquisition in China? - The acquisition was primarily to add capacity and enhance local production capabilities in response to growing demand in the region [97] Question: How is the company positioned regarding margin improvements in the construction market? - Management noted that despite volume declines, productivity improvements have been made, setting the stage for future growth when market conditions improve [94]

Financial Data and Key Metrics Changes - Third quarter sales reached $3.1 billion, reflecting a 6% organic growth [5][12] - Operating EBITDA was $840 million, an increase of 6% year-over-year, resulting in an operating EBITDA margin of 27.3% [6][12] - Adjusted EPS for the quarter was $1.09, flat compared to the previous year, with a higher tax rate impacting results [15][20] Business Line Data and Key Metrics Changes - Industrials Co. net sales were $1.8 billion, up 5% year-over-year, with organic growth of 4% [15][16] - Electronics Co. net sales increased to $1.3 billion, an 11% rise year-over-year, driven by 10% organic growth [17] - Healthcare and water technologies saw high single-digit organic growth, while diversified industrials experienced low single-digit growth [16][17] Market Data and Key Metrics Changes - North America and Asia-Pacific regions reported organic growth of 7%, while Europe saw a 6% increase year-over-year [14] - The construction market remains weak, with expectations of a 4% decline in the shelter business for the year [82] Company Strategy and Development Direction - The company is focused on driving above-market organic growth and maintaining a balanced capital allocation model [8][11] - A new quarterly dividend of $0.20 per share was declared, alongside a $2 billion share repurchase authorization [7][20] - The company aims for 3%-4% organic growth from 2026 to 2028, with a focus on healthcare and water technologies [11][92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving medium-term targets, despite current market challenges [92] - The healthcare and water segments are expected to grow at around 5% organically, while the diversified industrials segment is projected to remain flat [32][92] - The company is actively pursuing M&A opportunities, particularly in the healthcare sector [42][57] Other Important Information - The successful completion of the CUNY separation was highlighted, with $4.2 billion received to reduce debt [18] - The company is implementing enhanced KPIs to drive operational excellence and continuous improvement [9][46] Q&A Session Summary Question: Inquiry about end market trends and timing benefits - Management explained that the timing benefit was customer-driven, with orders accelerated into Q3 due to a planned blackout period [28][30] Question: Thoughts on exit rates and market conditions for 2026 - Management expects healthcare and water to align with medium-term targets, while the construction market is anticipated to stabilize [31][32] Question: Balance sheet plans and potential M&A activity - The company aims to maintain a pro forma debt below 2x EBITDA and is open to both share buybacks and M&A opportunities [39][42] Question: Discussion on operational excellence initiatives - A new Chief Operations Officer has been hired to enhance operational efficiency and implement a continuous improvement culture [44][46] Question: Strategic rationale for the RO acquisition in China - The acquisition was primarily for capacity expansion to meet local demand, without adding new technology [97] Question: Performance in the healthcare business and medical device space - The healthcare segment is expected to grow mid to high single digits, with strong performance in medical packaging and biopharma [79][80]

Financial Data and Key Metrics Changes - Third quarter sales reached $3.1 billion, reflecting a 6% organic growth year-over-year [5][12] - Operating EBITDA was $840 million, an increase of 6% year-over-year, resulting in an operating EBITDA margin of 27.3% [5][12] - Adjusted EPS for the quarter was $1.09, flat compared to the previous year, primarily due to a higher tax rate [14] Business Line Data and Key Metrics Changes - **Industrials Co.**: Net sales of $1.8 billion, up 5% year-over-year, with 4% organic growth [14][16] - **Electronics Co.**: Net sales of $1.3 billion, an increase of 11% year-over-year, driven by 10% organic growth [17] - Organic growth in healthcare and water technologies was in the high single digits, while diversified industrials saw low single-digit growth [15][16] Market Data and Key Metrics Changes - North America and Asia-Pacific regions experienced 7% organic growth, while Europe saw a 6% increase year-over-year [13] - The healthcare and water business is expected to grow at about 5% organic growth on average [31] Company Strategy and Development Direction - The company is focused on driving above-market organic growth and building a robust business system [7][11] - A disciplined capital allocation model was emphasized, including a quarterly dividend of $0.20 per share and a $2 billion share repurchase authorization [6][11] - The company aims for medium-term targets of 3%-4% organic growth, 150-200 basis points of margin expansion, and 8%-10% EPS growth from 2026 to 2028 [11][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving medium-term targets, with expectations of continued growth in healthcare and water sectors [31][92] - The construction market is anticipated to improve, with expectations of flat performance in the shelter business next year [82][93] Other Important Information - The successful completion of the CUNY separation was highlighted, with $4.2 billion received to reduce debt [18] - The company is actively pursuing M&A opportunities, particularly in healthcare and water sectors [41][53] Q&A Session Summary Question: Can you provide insight on the timing benefit in sales? - The timing benefit was customer-driven, as orders were accelerated into Q3 due to a planned blackout period for the separation [29] Question: What are the expectations for 2026? - The company expects healthcare and water to grow at about 5% organic growth, while the diversified industrials segment is projected to be flat [31][92] Question: What is the plan for the balance sheet? - The pro forma debt is expected to be around $3.25 billion, with a target to stay below 2 times net debt to EBITDA [39] Question: Can you elaborate on the RO acquisition in China? - The acquisition was primarily to add capacity and enhance local production capabilities, not to introduce new technology [97] Question: How is the healthcare business performing? - The healthcare business is expected to see mid to high single-digit growth, with strong performance in medical packaging and biopharma [80]

Financial Performance - Net sales reached $3.072 billion, a 7% increase compared to the previous year[65] - Organic sales grew by 6%, driven by electronics, healthcare, water, and industrials end-markets[14] - Operating EBITDA increased by 6% year-over-year to $840 million, attributed to organic growth and productivity[15] - Adjusted EPS remained consistent at $1.09 per share, with higher segment earnings offset by a higher tax rate[15] - Transaction-adjusted free cash flow from continuing operations was $576 million, representing a 126% conversion rate[15] Business Segments - IndustrialsCo's organic sales increased by 4%[15] - ElectronicsCo's organic sales increased by 10%[15] - Healthcare & Water Technologies sales increased by high-single digits organically[21] - Diversified Industrials sales increased by low-single digits organically[21] Strategic Initiatives - DuPont completed the spin-off of its Electronics business, Qnity, on November 1, 2025[3] - A definitive agreement was reached to sell the aramids business to TJC LP for approximately $1.2 billion in cash, a $300 million note, and a minority equity interest valued at $325 million[4] - A $2 billion share repurchase authorization was announced, with an initial $500 million accelerated share repurchase (ASR) expected to launch quickly[10] Guidance - Full-year 2025 operating EBITDA guidance was raised to approximately $1.6 billion[28] - Full-year 2025 net sales are projected to be approximately $6.840 billion[29] - Full-year 2025 adjusted EPS is projected to be approximately $1.66[29]

Core Insights - DuPont reported third-quarter earnings per share of $1.09 from sales of $3.1 billion [1] - The results are not comparable to consensus estimates due to the completion of the Qnity Electronics spinoff earlier in the week [1] Financial Performance - Earnings per share for the third quarter stood at $1.09 [1] - Total sales for the quarter were reported at $3.1 billion [1] Corporate Actions - The Qnity Electronics spinoff was completed earlier in the week, impacting the comparability of the results [1]

Core Insights - DuPont reported third-quarter sales of $3.07 billion and expects adjusted earnings per share of approximately $0.43 for the fourth quarter [1] Group 1 - The third-quarter sales figure of DuPont is $3.07 billion [1] - The company anticipates an adjusted earnings per share of about $0.43 for the upcoming fourth quarter [1]

Core Insights - DuPont de Nemours reported an increase in third-quarter sales, indicating positive performance in the market [1] - The company authorized a stock repurchase program worth $2 billion, reflecting confidence in its financial health and future prospects [1] - A quarterly dividend of 20 cents per share was declared, demonstrating a commitment to returning value to shareholders [1]

Financial Performance - DuPont reported strong third-quarter 2025 financial results, with sales of $3.07 billion, surpassing the estimated $2.90 billion [2][9] - Adjusted earnings per share (EPS) for DuPont were $1.09, exceeding forecasts of $1.06 [2][9] - Operating EBITDA reached $840 million, slightly above the estimate of $839.7 million [2][9] - DuPont's outlook for the fourth quarter projects net sales of approximately $1.69 billion and adjusted EPS of about $0.43, both slightly below analyst expectations [2][9] Regulatory Developments - The European Commission has initiated a formal antitrust investigation into Deutsche Boerse and Nasdaq, focusing on potential collusion in the listing, trading, and clearing of financial derivatives [3][9] - Concerns include possible agreements not to compete, allocation of demand, coordinated pricing, and the exchange of commercially sensitive information [3][9] Market Trends - Soybean prices surged to their highest point in 17 months, driven by expectations of renewed large-scale U.S. soybean purchases by China [4][9] - U.S. stock futures turned positive, indicating a generally optimistic market sentiment, with S&P 500 E-mini futures up 0.08%, Nasdaq 100 futures gaining 0.07%, and Dow futures seeing a 0.01% increase [5][9] Economic Impact - The Bank of Italy commented on the government's tax hike measures, indicating that these are expected to affect the banking sector, while the impact on insurers is projected to be limited [6][9] - The Italian government's 2026 budget plans include an €11 billion ($12.8 billion) tax increase on banks and insurance firms over 2026-2028 [6][9]